Exact Sciences Missed Expectations

Exact Sciences (EXAS) reported a loss of $0.21 per share on revenue of $706.79 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.37 per share on revenue of $689.35 million. The Earnings Whisper number was a loss of $0.20 per share. The company missed expectations by 5.00% while revenue grew 10.86% on a year-over-year basis.

The company said it expects 2025 revenue of $3.07 billion to $3.12 billion. The company's previous guidance was revenue of $3.025 billion to $3.085 billion and the current consensus revenue estimate is $3.05 billion for the year ending December 31, 2025.

Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non-invasive, patient friendly screening test called Cologuard(R).